News

New Gene Therapy Study

The Phase I Gene Therapy Study for Fabry Disease is looking to recruit interested patients. This is a first-in-human study for the treatment of Fabry disease.

Shares
News

From pain to empowerment with Fabry disease

Approximately 1/12 Canadians are affected by a rare disease and prompt diagnosis is imperative as symptom management, and treatment options can drastically improve quality of life. Share the message of awareness and find what makes you rare. Maclean’s Photo Credit: Patrick Chondon http://www.macleans.ca/sponsored/from-pain-to-empowerment-with-fabry-disease/

Shares
Event

Webinar Wednesday (February 21st 2018)

Information on the Webinar hosted by Julia Alton

Shares
News

Happy Holidays!

Happy Holidays from the Canadian Fabry Association!

Shares
Event

Webinar Wednesday (January 3rd 2018)

Information on the Webinar hosted by Julia Alton

Shares
News

Replagal Approved by Health Canada

Exciting news for the CFA Community – Replagal has been approved by Health Canada as of February 2017 and all patients have been transitioned from the REP-081 study at this point. Replagal is a long-term Enzyme Replacement Therapy (ERT), the infusion will be given every 2 weeks, treatment time being approximately 4o minutes. It is […]

Shares
News

Galafold Approval

Excited to share Health Canada’s approval of the oral- precision medicine Galafold! We look forward to this differentiated treatment option for Canadian patients with amenable mutations. Please see the press release for further information.

Shares
Event

Patient Empowerment Pilot Project

Ontario Patients – Please join us for our very first Patient Empowerment Pilot Project Workshop.

Shares
News

Rare Disease Heroes – Kaye LeMoine

The CFA is honoured and proud to share this Rare Disease Hero Video featuring Kaye LeMoine….

Shares
News

Dr. West / Resverlogix and Apabetalone

In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.

Shares
News

Join the Board

The Board is responsible for the highest level of decision-making and communicates the organization’s vision to all members and the community.

Shares
Close

Contact Us

If have any questions or would like to get involved, please fill in the form below.

Subscribe error, please review your email address.

Close

You're now subscribed, thank you!

Close

There was a problem with your submission. Please check the field(s) with red label below.

Close

Your message has been sent. We'll get back to you soon!

Close